Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business
Alasdair Pal and Euan Rocha

US, India, Australia, Japan agree to send one billion vaccines across Asia by end-2022

FILE PHOTO:Syringes sit on a table where coronavirus disease vaccines are being administered during a two-day COVID-19 vaccination clinic inside the JBS Greeley Beef plant in Greeley, Colorado, U.S., March 5, 2021. Alex McIntyre/The Greeley Tribune/Pool

Leaders of the United States, India, Australia and Japan agreed to pool financing, manufacturing and distribution capacity to send 1 billion coronavirus vaccines across Asia by the end of 2022, India's foreign secretary said on Friday.

The so-called "Quad" group of four nations want to expand global vaccinations and counter China's growing vaccination diplomacy in Southeast Asia and around the world. India is the world's biggest vaccine maker.

The collaboration was "most pressing and valuable", foreign secretary Harsh Vardhan Shringla told a news conference in India's capital New Delhi after the four-way virtual summit.

"The four countries have agreed to a plan to pool their financial resources, manufacturing capabilities and capacities, and logistical strengths so as to ramp up the manufacturing and distribution of the COVID-19 vaccines in the Indo-Pacific region," he said.

"We believe this will speed up the process of post-pandemic recovery and enable families and businesses to put the COVID-19 crisis behind them."

India will use its manufacturing capacity to make U.S. vaccines, with financing coming from the U.S. International Development Finance Corporation and the Japan Bank for International Cooperation.

Australia will finance training and provide last-mile logistical support for the distribution of vaccines, he added, that will predominantly go to the Pacific Islands, Southeast Asia and countries in the Indian Ocean.

The initiative, however, may be hampered by U.S. export restrictions on critical raw materials for India's vaccine supply chain.

Shringla said the issue is a bilateral one with the United States that has been raised by India's ambassador in Washington.

"Consideration is being given to this very important point," he said, without elaborating.

The tie-up will not impact the production of vaccines for India's 1.4 billion people, Shringla added.

(Reporting by Alasdair Pal in New Delhi and Euan Rocha in Mumbai; Editing by Hugh Lawson)

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.